157 related articles for article (PubMed ID: 27665209)
1. Harm reduction workers and the challenge of engaging couples who inject drugs in hepatitis C prevention.
Treloar C; Rance J; Bryant J; Fraser S
Drug Alcohol Depend; 2016 Nov; 168():170-175. PubMed ID: 27665209
[TBL] [Abstract][Full Text] [Related]
2. Practices of partnership: Negotiated safety among couples who inject drugs.
Rance J; Rhodes T; Fraser S; Bryant J; Treloar C
Health (London); 2018 Jan; 22(1):3-19. PubMed ID: 27491943
[TBL] [Abstract][Full Text] [Related]
3. "Don't think I'm going to leave you over it": Accounts of changing hepatitis C status among couples who inject drugs.
Rance J; Treloar C; Fraser S; Bryant J; Rhodes T
Drug Alcohol Depend; 2017 Apr; 173():78-84. PubMed ID: 28208098
[TBL] [Abstract][Full Text] [Related]
4. A qualitative study trialling the acceptability of new hepatitis C prevention messages for people who inject drugs: symbiotic messages, pleasure and conditional interpretations.
Treloar C; Newland J; Maher L
Harm Reduct J; 2015 Mar; 12():5. PubMed ID: 25884357
[TBL] [Abstract][Full Text] [Related]
5. 'Affording' new approaches to couples who inject drugs: A novel fitpack design for hepatitis C prevention.
Fraser S; Treloar C; Gendera S; Rance J
Int J Drug Policy; 2017 Dec; 50():19-35. PubMed ID: 28982041
[TBL] [Abstract][Full Text] [Related]
6. Understanding decisions made about hepatitis C treatment by couples who inject drugs.
Treloar C; Rance J; Bryant J; Fraser S
J Viral Hepat; 2016 Feb; 23(2):89-95. PubMed ID: 26305873
[TBL] [Abstract][Full Text] [Related]
7. Injecting practices in sexual partnerships: hepatitis C transmission potentials in a 'risk equivalence' framework.
Harris M; Rhodes T
Drug Alcohol Depend; 2013 Oct; 132(3):617-23. PubMed ID: 23664125
[TBL] [Abstract][Full Text] [Related]
8. Engaging people who inject drugs in hepatitis C virus testing and prevention through community-based outreach, in Sydney, Australia.
Coupland H; White B; Bates A; Park JN; Iversen J; Maher L
Drug Alcohol Rev; 2019 Feb; 38(2):177-184. PubMed ID: 30652363
[TBL] [Abstract][Full Text] [Related]
9. Using an intersectionality lens to explore barriers and enablers to hepatitis C point-of-care testing: a qualitative study among people who inject drugs and service providers.
Fontaine G; Presseau J; Bruneau J; Etherington C; Thomas IM; Hung JC; van Allen Z; Patey AM; Kareem A; Mortazhejri S; Høj SB; Boyer-Legault G; Grimshaw JM
Int J Equity Health; 2024 Jun; 23(1):124. PubMed ID: 38886803
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.
Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ
Int J Drug Policy; 2015 Oct; 26(10):992-8. PubMed ID: 25697089
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.
Todd CS; Nasir A; Stanekzai MR; Fiekert K; Sipsma HL; Vlahov D; Strathdee SA
Harm Reduct J; 2015 Oct; 12():22. PubMed ID: 26472126
[TBL] [Abstract][Full Text] [Related]
12. The missing mass of morality: a new fitpack design for hepatitis C prevention in sexual partnerships.
Fraser S
Int J Drug Policy; 2013 May; 24(3):212-9. PubMed ID: 23602226
[TBL] [Abstract][Full Text] [Related]
13. Qualitative accounts of needle and syringe cleaning techniques among people who inject drugs in Sydney, Australia.
Nathani J; Iversen J; Shying K; Byrne J; Maher L
Drug Alcohol Rev; 2010 Jul; 29(4):413-9. PubMed ID: 20636658
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with sharing equipment among people who inject drugs: The role of community attachment in harm reduction and health promotion.
Broady TR; Brener L; Caruana T; Cama E; Treloar C
Drug Alcohol Rev; 2023 Mar; 42(3):561-568. PubMed ID: 36729689
[TBL] [Abstract][Full Text] [Related]
15. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
Hallinan R; Byrne A; Dore GJ
Drug Alcohol Rev; 2007 Jul; 26(4):437-43. PubMed ID: 17564882
[TBL] [Abstract][Full Text] [Related]
16. Innovative community-based educational face-to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious risks in difficult-to-reach people who inject drugs: results from the ANRS-AERLI intervention study.
Roux P; Le Gall JM; Debrus M; Protopopescu C; Ndiaye K; Demoulin B; Lions C; Haas A; Mora M; Spire B; Suzan-Monti M; Carrieri MP
Addiction; 2016 Jan; 111(1):94-106. PubMed ID: 26234629
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty.
Rhodes T; Davis M; Judd A
Addiction; 2004 May; 99(5):621-33. PubMed ID: 15078237
[TBL] [Abstract][Full Text] [Related]
18. Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: A systematic review.
Caven M; Malaguti A; Robinson E; Fletcher E; Dillon JF
Int J Drug Policy; 2019 Oct; 72():169-176. PubMed ID: 31109776
[TBL] [Abstract][Full Text] [Related]
19. Change in injecting behaviour among people treated for hepatitis C virus: The role of intimate partnerships.
Malaguti A; Sani F; Stephens BP; Ahmad F; Dugard P; Dillon JF;
J Viral Hepat; 2019 Jan; 26(1):65-72. PubMed ID: 30260560
[TBL] [Abstract][Full Text] [Related]
20. Rural risk environments for hepatitis c among young adults in appalachian kentucky.
Cloud DH; Ibragimov U; Prood N; Young AM; Cooper HLF
Int J Drug Policy; 2019 Oct; 72():47-54. PubMed ID: 31113713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
